Browse by category

Amylyx Pharmaceuticals has announced positive topline results from LUCIDITY, a 78-participant, multi-centre, randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. LUCIDITY met the FDA-agreed-upon primary endpoint demonstrat

Amylyx Pharmaceuticals plans to initiate a Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class...

Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe...